Australian Gonococcal Surveillance Programme annual report, 2012
DOI:
https://doi.org/10.33321/cdi.2013.37.35Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian Gonococcal Surveillance Programme has continuously monitored antimicrobial resistance in clinical isolates of Neisseria gonorrhoeae from all states and territories since 1981. In 2012, 4,718 clinical isolates of gonococci from public and private sector sources were tested for in vitro antimicrobial susceptibility by standardised methods. Variation in antibiotic susceptibility patterns were reported between jurisdictions and regions. Resistance to the penicillins and quinolones was high in all jurisdictions except the Northern Territory and Tasmania. Penicillin resistance ranged from 21% in Western Australia to 53% in Victoria. Quinolone resistance ranged from 17% in Queensland to 46% in Victoria, and the resistance was mostly high level. Decreased susceptibility to ceftriaxone (MIC 0.06–0.25 mg/L) was found nationally in 4.4% of isolates, an increase from 3.2% in 2011, but lower than in 2010. To date, there has not been an isolate of N. gonorrhoeae with a ceftriaxone MIC value greater than 0.125 mg/L reported in Australia. Azithromycin susceptibility testing was performed in all jurisdictions and resistance ranged from 0.3% in the Northern Territory to 2.7% in Victoria. The highest reported azithromycin MIC value was 16 mg/L and azithromycin resistant gonococci were not detected in the Australian Capital Territory or Tasmania. Nationally, all isolates remained susceptible to spectinomycin. Commun Dis Intell 2013;37(3):E233–E239.
Downloads
References
World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS response: Epidemic update and health sector progress towards universal access. Progress report 2011. Geneva, Switzerland: World Health Organization. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_ua_report_en.pdf
Australian Government Department of Health. National Notifiable Diseases Surveillance System dataset. Accessed in 2013. Available from: http://www9.health.gov.au/cda/source/cda-index.cfm
Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: some possible remedies. Expert Rev Anti Infect Ther 2006;4(4):619–628.
Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009;22(1):87–91.
Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug– and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7(7):821–834.
Tapsall JW, Limnios EA, Murphy DM. An analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997–2006. J Antimicrob Chemother 2008; 61(1) 150–155.
Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85(4):256–258.
Lahra M. Annual report of the Australian Gonococcal Surveillance Programme, 2011. Commun Dis Intell 2012;36(2):E166–E173.
Chen M, Stevens K, Tideman R, Zaia A, Tomita T, Fairley C, et al. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013;68(6):1445–1447.
Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58(Pt 5):683–687.
Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55(7):3538–3545.
Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012;67(8):1858–1860.
Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect 2010;86(6):415–421.
World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae: Geneva, Switzerland: WHO Department of Reproductive Health and Research; 2012.
Tapsall J. Penicillin sensitivity of gonococci in Australia: the development of an Australian Gonococcal Surveillance Programme. Br J Vener Dis 1984;60(4):226–230.
Tapsall J, ed. Antimicrobial testing and applications in the pathogenic Neisseria. Sydney: Australian Society for Microbiology; 2004.
Tapsall J. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourin Med 1990;66(1):437–444.
Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63(6):1142–1151.
Lahra MM. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2010. Commun Dis Intell 2012;36(1):95–100.
Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime– and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56(3):1273–1280.
Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16(6):11.
Lo J, Ho K, Leung A, Tiu F, Tsang G, Lo A, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52(10):3564–3567.
Whiley DM, Goire N, Lahra MM, Donovan B, Limnios AE, Nissen MD, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012;67(9):2059–2061.
Bignell C, FitzGerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011;22(10):541–547.
Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61(31):590–594.
Katz AR, Komeya AY, Soge OO, Kiaha MI, Lee MVC, Wasserman GM, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012;54(6):841–843.
Yuan LF, Yin YP, Dai XQ, Pearline RV, Xiang Z, Unemo M, et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011;38(8):764–768.
Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148(8):606–613.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2013 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
